AMAG Pharma (AMAG) Tops Q3 EPS by 31c

AMAG Pharma (NASDAQ: AMAG) reported Q3 EPS of $1.81, $0.31 better than the analyst estimate of $1.50. Revenue for the quarter came in at $143.8 million versus the consensus estimate of $141.48 million.

GUIDANCE:

AMAG Pharma sees FY2016 revenue of $523-553 million, versus prior guidance of $503-553 million and the consensus of $543.0 million.

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Logistic Properties of the Americas (LPA) Reports Q2 results
• Aptera Motors (SEV) Reports Q2 Loss of $0.20